Industry Overview

Brain and spinal cord cancer market was valued at $7.0 billion in 2025 and is projected to reach $13.3 billion by 2035, growing at a CAGR of 6.8% during the forecast Period (2026-2035). The Market is witnessing steady growth driven by increasing demand for innovative display solutions across automotive, retail, consumer electronics, and advertising sectors. Transparent displays offer enhanced user experiences by overlaying digital information onto real-world objects, enabling applications such as heads-up displays, smart windows, and interactive signage. The market encompasses technologies including Transparent Liquid Crystal Displays (LCDs), Transparent Light-Emitting Diodes (LEDs), Transparent Plasma Display Panels (PDPs), and emerging electrochemical and electrowetting displays. Advancements in materials, improved transparency, and energy efficiency are supporting wider adoption. North America and Asia-Pacific remain key markets due to technological innovation, high consumer awareness, and industrial investments.

Market Dynamics

Rising Incidence and Prevalence of Brain and Spinal Cord Cancers

One of the foremost drivers of the global brain and spinal cord cancer market is the increasing incidence and prevalence of central nervous system (CNS) tumors worldwide. Epidemiological data indicates a notable rise in diagnoses of malignant brain and spinal cord tumors, reflecting both true increases in disease and improvements in detection rates. As the global population ages and risk factors like ionizing radiation exposure, genetic predispositions, and lifestyle influences persist, more patients are being diagnosed with CNS neoplasms, thereby expanding the demand for advanced diagnostic and therapeutic solutions. This growth in patient population creates a sustained requirement for comprehensive care pathways, including imaging diagnostics, surgical interventions, and innovative treatments such as targeted therapies and immunotherapies.

Advancements in Diagnostic and Treatment Technologies

Technological progress in both diagnostic imaging and treatment modalities is a major catalyst propelling market growth. High?resolution imaging techniques including advanced MRI, CT, and PET scans improve early detection, accurate staging, and treatment planning, driving increased utilization of diagnostic services. Simultaneously, breakthroughs in therapeutic technologies, such as minimally invasive surgical techniques, precision radiotherapy approaches, and next?generation targeted and immunotherapy agents, are transforming clinical outcomes by offering more effective, personalized treatment regimens. Innovations like tumor?treating fields (TTFields), laser?based therapies, and enhanced neuro?navigation systems are redefining standards of care, encouraging healthcare providers and patients alike to adopt advanced options that improve survival and quality of life.

Growing R&D Investment and Healthcare Infrastructure Expansion

Heightened investment in research and development (R&D) and the expansion of healthcare infrastructure globally are important market growth drivers. Pharmaceutical companies, biotechnology firms, and academic institutions are increasing spending on clinical research aimed at discovering novel therapeutics and improving existing treatment protocols, particularly in personalized medicine and molecularly targeted approaches. Government initiatives and grant funding in major markets further support innovation pipelines, accelerating clinical trial activity and regulatory approvals for new cancer treatments. In addition, rising healthcare expenditure, especially in emerging economies, is expanding access to advanced diagnostic and treatment facilities, enabling broader adoption of cutting?edge oncology care. This infrastructure growth coupled with rising awareness among clinicians and patients is fostering a more dynamic, competitive landscape that contributes to sustained market expansion.

Market Segmentation

• Based on the type, the market is segmented into grade I, grade II, grade III and grade IV).
• Based on the diagnostic test, the market is segmented into imaging tests, magnetic resonance imaging (MRI) scan, computed tomography (CT) scan and positron emission tomography (PET) scan.
• Based on the treatment, the market is segmented into surgery and therapy.

Grade IV Segment to Grow at a Considerable Market Share

Grade IV brain and spinal cord cancer segment is expected to dominate due to its high severity, aggressive nature, and urgent treatment requirements. Grade IV tumors, including glioblastomas, are characterized by rapid growth, invasiveness, and poor prognosis, driving the need for advanced diagnostic and therapeutic interventions. The high incidence of Grade IV tumors globally, coupled with increasing awareness and early detection efforts, ensures substantial demand for specialized imaging technologies such as MRI, CT, and PET scans, which aid in accurate diagnosis, staging, and treatment planning. In parallel, the complexity of Grade IV tumors necessitates intensive treatment approaches, with surgery and post-operative therapies being critical components of patient management. This requirement significantly boosts the adoption of cutting-edge surgical procedures, precision radiotherapy, and targeted or immunotherapy treatments, creating higher revenue potential compared to lower-grade tumors.

 Moreover, healthcare providers are investing in advanced hospital and diagnostic infrastructure to handle the increasing number of severe cases, while ongoing R&D efforts focus on novel therapeutic options to improve survival outcomes. Collectively, the high prevalence, aggressive progression, and need for comprehensive care make the Grade IV segment the largest and most influential driver of revenue in the global brain and spinal cord cancer market, setting it apart from other grades, diagnostic tests, and treatment types.

Imaging Tests: A Key Segment in Market Growth

Imaging tests represent the fastest-growing and most critical segment of the market. Imaging technologies, including Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography (PET), have become indispensable for early detection, accurate diagnosis, and precise treatment planning of central nervous system tumors. MRI, in particular, offers high-resolution, non-invasive visualization of brain and spinal cord structures, enabling clinicians to identify tumor location, size, and infiltration patterns with unmatched accuracy. The increasing adoption of advanced imaging protocols, such as functional MRI and diffusion tensor imaging, further enhances diagnostic precision and guides surgical or therapeutic interventions. Rising awareness among healthcare providers and patients about the importance of early detection, coupled with continuous technological innovations in imaging modalities, is significantly driving demand.

Moreover, hospitals and diagnostic centers are investing heavily in upgrading imaging infrastructure, expanding accessibility across both developed and emerging markets. Regulatory support for innovative diagnostic devices and the integration of imaging with artificial intelligence and machine learning for predictive analytics further reinforce this segment’s growth. As a result, imaging tests are expected to remain the primary revenue contributor and the key driver shaping the expansion of the global brain and spinal cord cancer market over the forecast period.

Regional Outlook

The global brain and spinal cord cancer market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US is the leading country in the global brain and spinal cord cancer market, accounting for the largest share in terms of both revenue and technological adoption. The dominance of the US market can be attributed to a combination of factors, including the high prevalence of central nervous system (CNS) tumors, advanced healthcare infrastructure, and significant investments in research and development for cancer diagnostics and therapeutics. The presence of world-class hospitals, specialty cancer centers, and highly skilled medical professionals enables widespread access to advanced diagnostic imaging modalities such as MRI, CT, and PET scans, which are critical for early detection and accurate treatment planning.

Additionally, the US benefits from strong government and private sector support for oncology research, leading to the rapid approval and commercialization of innovative therapies, including minimally invasive surgical techniques, targeted therapies, and immunotherapies. High healthcare expenditure and well-established reimbursement frameworks further facilitate the adoption of cutting-edge diagnostic and treatment options. Furthermore, the country’s focus on personalized medicine and precision oncology, along with ongoing clinical trials for novel CNS cancer treatments, reinforces its leadership position. Collectively, these factors make the United States the primary driver of global market growth, setting benchmarks for both technological advancement and clinical care in brain and spinal cord cancer management.

Market Players Outlook

the major companies operating in the global brain and spinal cord cancer market include Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc. among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

• In November 2025, New research from the Children's Hospital of Philadelphia and Children's National Hospital reveals that rare inherited genetic variants contribute to the development of brain and spinal cord tumors in children. Published in Nature Communications, the study emphasizes the connection between a child’s genetic makeup and cancer risk. Central nervous system cancers are the leading cause of cancer-related deaths in children, with a notable percentage (23.3%) carrying genetic changes increasing their cancer risk. The investigation notes that many genetic risks for these tumors remain undetected, suggesting a need for comprehensive genetic screening in pediatric patients.
• In August 2025, FDA approved ONC201 (dordaviprone) for the treatment of recurrent H3K27M-mutant diffuse glioma, a deadly pediatric brain tumor that typically leads to a fatal prognosis within 9 to 15 months of diagnosis. This approval offers new hope in the fight against diffuse midline glioma (DMG), which is characterized by a specific mutation found in pediatric patients.
• In September 2025, Research from the UNC School of Medicine and Madera Therapeutics has led to the FDA approval of dordaviprone, the first medication for diffuse midline glioma, a rare and fatal brain cancer affecting 2,000 children and young adults annually in the U.S. This weekly capsule therapy has been shown to shrink tumors and extend patient lifespans, offering new hope for those affected. Dr. Lee Graves and his team were instrumental in understanding how dordaviprone (ONC201) and similar compounds work to halt cancer progression.

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global brain and spinal cord cancer market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.